Efficacy and safety of (188)Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study

CONCLUSIONS: 188Re-HEDP at dose of 40 and 50 MBq/kg was generally effective to alleviate pain and improve QOL in lung cancer patients with painful bone metastases. 188Re-HEDP was safe and well-tolerated.PMID:33847856 | DOI:10.1007/s10147-021-01906-y

Source: Clinical Lung Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Ping Chen Jun Li Jicong Gui Congjin Liu Yuankai Wang Guangming Zhang Dayu Kuai Yiwei Wu Zengli Liu Changjing Zuo Zhongwei Lv Yingjian Biao ZhangLi Xingdang Liu Source Type: research